This is a retrospective and prospective cohort study designed to evaluate the recurrence rate and identify risk factors after endoscopic resection of gastric and intestinal polyps.
BACKGROUND: Gastric and intestinal polyps are common digestive diseases with potential for malignant transformation. Although endoscopic resection is the standard treatment, recurrence rates range from 10-50%, and the mechanisms and risk factors remain unclear.
OBJECTIVES:
Primary: To assess short-term (1-year) and long-term (3-year) recurrence rates after endoscopic polyp resection Secondary: To identify independent risk factors and develop a recurrence risk prediction model
DESIGN: Mixed retrospective-prospective cohort study
* Retrospective cohort: Patients who underwent polyp resection from 2021-2022, with follow-up data through 2024 * Prospective cohort: Patients enrolled from 2024-2025, with standardized follow-up through 2028
SETTING: Single tertiary referral center with \>10,000 endoscopic polyp resections performed since 2021
PARTICIPANTS: Approximately 1,600-1,800 adult patients (≥18 years) who underwent complete endoscopic resection of gastric or intestinal polyps
FOLLOW-UP:
* Short-term: 1 year post-resection (±2 months) * Long-term: 3 years post-resection (±3 months)
MAIN OUTCOME: Recurrence rate defined as new polyp detection at original or different sites during endoscopic surveillance
POTENTIAL RISK FACTORS: Patient demographics, polyp characteristics (size, number, location, pathology), resection method, Helicobacter pylori status, lifestyle factors, and medication use
EXPECTED IMPACT: Results will inform personalized surveillance strategies and optimize resource allocation for post-polypectomy follow-up.
Age 18 years or older
First-time endoscopic examination (gastroscopy or colonoscopy) at the study center
Pathologically confirmed polyp of any type (adenomatous, hyperplastic, inflammatory, fundic gland polyp, hamartomatous, serrated lesion)
Complete endoscopic resection performed (including EMR, ESD, snare polypectomy, hot biopsy forceps, or argon plasma coagulation)
Hereditary polyposis syndromes (familial adenomatous polyposis, Lynch syndrome, Peutz-Jeghers syndrome, juvenile polyposis syndrome)
Inflammatory bowel disease (ulcerative colitis or Crohn's disease)
Previous history of gastric or colorectal cancer
Cancer detected at initial resection (stage T1b or higher)
The study population consists of adult patients (≥18 years) who underwent complete endoscopic resection of gastric or intestinal polyps at our tertiary referral center. This includes two cohorts: (1) Retrospective cohort: patients treated from 2021-2022 with existing follow-up data; (2) Prospective cohort: newly enrolled patients from 2024-2025. Eligible participants must have pathologically confirmed polyps (adenomatous, hyperplastic, inflammatory, fundic gland, serrated, or hamartomatous) with negative resection margins. The population represents a diverse group with varying polyp characteristics (size range: \<5mm to \>20mm; single or multiple polyps; gastric or colorectal locations) and different resection methods (EMR, ESD, snare polypectomy). Excluded are patients with hereditary polyposis syndromes, inflammatory bowel disease, prior gastrointestinal malignancy, or cancer detected at initial resection.
Cohort
Other
Not listed
Short-term Recurrence Rate at 1 Year
New polyp(s) detected by endoscopy and confirmed by pathology at 1-year follow-up. Includes both local recurrence (within 2cm of resection site) and metachronous polyps (\>2cm from original site).
Long-term Recurrence Rate at 3 Years
New polyp(s) detected by endoscopy and confirmed by pathology at 3-year follow-up. Includes both local recurrence and metachronous polyps.
Cumulative Recurrence Rate
Overall recurrence rate combining 1-year and 3-year surveillance results
Recurrence-free Survival Time
Measured in months; censored at last follow-up for non-recurrent cases
Characteristics of Recurrent Polyps
Descriptive analysis of recurrent polyp features: Number, size, location, and pathological type of recurrent polyps.
Progression to High-grade Dysplasia or Cancer
Pathologically confirmed progression: Proportion of participants developing high-grade dysplasia or invasive cancer during follow-up.
Re-treatment Rate
Proportion of participants requiring repeat endoscopic or surgical treatment: Includes repeat polypectomy, endoscopic resection, or surgical resection
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
